Lexicon and Ipsen's telotristat etiprate Phase III trial meets primary endpoint

3 August 2015
ipsen-logo-big

USA-based Lexicon Pharmaceuticals (Nasdaq: LXRX) and its partner French drugmaker Ipsen (Euronext: IPN) have announced positive results from their TELESTAR Phase III clinical trial of oral telotristat etiprate.

The trial examined telotristat etiprate in treating cancer patients with carcinoid syndrome that is not adequately controlled by the current standard of care. It is the first treatment discovered by Lexicon to complete a pivotal Phase III trial. If approved, it would be the first oral treatment successfully developed for carcinoid syndrome, and the first addition to standard of care in 16 years.

Top-line data from the study showed patients who added telotristat etiprate to the standard of care at 250mg and 500mg doses experienced a statistically-significant reduction from baseline compared to placebo in the average number of daily bowel movements over the 12-week study period, meeting the study’s primary endpoint.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical